Allergan Plc (AGN) 255.19 $AGN
How Short Sellers Run this Market: Part 1
at The Street - 1 hr 5 mins ago
First, the sectors where shorts are making big money.
KMI: 30.04 (-1.38), AGN: 255.19 (-3.81), HCA: 65.91 (-5.29), VRX: 101.29 (-17.32), SWKS: 80.45 (+2.78), CYH: 27.21 (-13.34), NXPI: 95.40 (+4.08), AVGO: 124.48 (+3.98), HRZN: 9.94 (+0.20)
RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off
at The Street - 2 hrs 2 mins ago
The selloff in specialty pharmaceutical stocks has found a new "irrational low," following Wednesday's attack on Valeant Pharmaceuticals, according to RBC Capital Markets.
AGN: 255.19 (-3.81), ENDP: 49.51 (-4.95), INSY: 22.00 (-1.66), VRX: 101.29 (-17.32), SGNT: 15.57 (-0.49), IBB: 304.36 (-0.10), TEVA: 56.07 (-1.85)
Trigeminal Neuralgia Pipeline Review, H2 2015 - 4 Companies & 5 Drug Profiles
M2 - Thu Oct 22, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t353hr/trigeminal) has announced the addition of the "Trigeminal Neuralgia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Trigeminal Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Trigeminal Neuralgia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Convergence Pharmaceuticals Ltd. - Merz Pharma GmbH & Co. KgaA - Trigemina, Inc. Drug Profiles - (naltrexone hydrochloride clonidine hydrochloride) - incobotulinumtoxin A - onabotulinumtoxin A - oxytocin - raxatrigine hydrochloride For more information visit http://www.researchandmarkets.com/research/t353hr/trigeminal
AGN: 255.19 (-3.81)
Valeant Dives As Short Seller Alleges Pharmacy Fraud
at Investor's Business Daily - Wed Oct 21, 4:02PM CDT
Embattled drugmaker Valeant Pharmaceuticals (VRX) tumbled nearly 40% Wednesday to a two-year low and closed down 19.2%, as short-selling outfit Citron Research charged it with a complex fraud involving multiple specialty pharmacies. Valeant responded...
AGN: 255.19 (-3.81), ENDP: 49.51 (-4.95), VRX: 101.29 (-17.32)
Ocular (OCUL) Initiates Third Phase III Study on Dextenza
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 3:25PM CDT
Ocular (OCUL) initiated patient enrolment in the third phase III study on Dextenza for the treatment of post-surgical ocular inflammation and pain.
AGN: 255.19 (-3.81), OCUL: 15.10 (-0.22), NVS: 92.25 (+0.66)
Allergan Issues Statement On Specialty Pharmacy Utilization
PR Newswire - Wed Oct 21, 11:07AM CDT
Allergan plc (NYSE: AGN), today issued the following statement regarding specialty pharmacy utilization.
AGN: 255.19 (-3.81)
Next Support Level for Allergan (AGN) is $248.35
Comtex SmarTrend(R) - Wed Oct 21, 9:05AM CDT
Allergan (NYSE:AGN) has opened bearishly below the pivot of $265.04 today and has reached the first level of support at $255.88. Investors may be interested in a cross of the next downside pivot targets of $248.35 and $231.66.
AGN: 255.19 (-3.81)
Allergan Expands Dry Eye Portfolio With Launch Of REFRESH OPTIVE® Gel Drops
PR Newswire - Wed Oct 21, 7:01AM CDT
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the launch of the over-the-counter artificial tear REFRESH OPTIVE® Gel Drops, a new aqueous gel expertly designed for patients who need or desire a more viscous artificial tear option to relieve their Dry Eye symptoms. From REFRESH®, the creators of the number one doctor recommended brand of artificial tears1, new REFRESH OPTIVE® Gel Drops are formulated with Glycerin and a unique blend of the active ingredient CMC which binds to the eye surface to provide long-lasting relief from Dry Eye discomfort.
AGN: 255.19 (-3.81)
SmarTrend Watching for Potential Rebound in Shares of Allergan After 3.62% Loss
Comtex SmarTrend(R) - Tue Oct 20, 3:45PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $257.50 to a high of $274.19. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $261.17 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 255.19 (-3.81)
Cempra Antibiotic Meets Endpoints, Adverse Events Concerning
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:35PM CDT
Cempra, Inc. (CEMP) announced positive top-line results from a global, phase III study on pipeline candidate intravenous to oral solithromycin.
AGN: 255.19 (-3.81), PFE: 33.15 (-0.31), CEMP: 17.03 (-0.01)
Supernus Inks Trokendi XR Settlement Agreement with Endo
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:25PM CDT
Supernus (SUPN) inked a settlement agreement with Par Pharmaceutical (Endo's wholly owned subsidiary) for an ongoing patent litigation regarding Trokendi XR.
AGN: 255.19 (-3.81), ENDP: 49.51 (-4.95), ADHD: 6.48 (-0.01), SUPN: 15.31 (-0.50)
Rotation Is Enough to Make Your Head Spin
at The Street - Tue Oct 20, 1:17PM CDT
Bad news isn't always a bad thing.
AMZN: 566.29 (+10.52), TSLA: 214.62 (+4.53), VRX: 101.29 (-17.32), HOG: 47.40 (+0.37), LMT: 216.74 (+5.18), ETN: 54.75 (+2.23), CLX: 123.30 (+1.24), UTX: 99.71 (+1.74), DAL: 50.79 (+1.35), CELG: 116.25 (+0.33), AGN: 255.19 (-3.81), GILD: 102.01 (+0.28), IBM: 144.54 (+3.62), GOOGL: 681.92 (+10.12), DOV: 65.05 (+3.17), PG: 75.02 (+1.43), PPG: 103.76 (+3.12), REGN: 520.57 (+2.04)
Global Physician Dispensed Cosmeceutical Industry - Reportlinker Review
PR Newswire - Tue Oct 20, 11:58AM CDT
This report analyzes the worldwide markets for Physician Dispensed Cosmeceuticals in US$ Thousand by the following Segments: Physician Dispensed Skin Care Products, and Physician Dispensed Eyelash Products. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 74 companies including many key and niche players such as -
AGN: 255.19 (-3.81)
ModiFace Launches Live Facial Rejuvenation and Enhancement Mirror in Partnership With Allergan Canada
Marketwired - Tue Oct 20, 8:01AM CDT
ModiFace, the leading creator of augmented reality technology for the beauty and medical aesthetic industries, today announces the upcoming availability of its rejuvenation and enhancement mirror that simulates the effects of JUVEDERM(R) facial filler, in real time video. This new technology allows those interested in facial revitalization treatments to view the potential results by looking at the ModiFace-powered digital mirror. The results are photo-realistic, and are shown with full 3D rendering, meaning that addition of volume and lifting of the face can be observed from all angles exactly as one would look into a regular mirror. You can apply over 10 JUVEDERM(R) treatment effects such as smoothing smile lines, enhancing lips and lifting cheeks.
AGN: 255.19 (-3.81)
Global BioPharma Cold Chain Packaging Market 2015-2019
M2 - Tue Oct 20, 6:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/639gfl/global_biopharma) has announced the addition of the "Global BioPharma Cold Chain Packaging Market 2015-2019" report to their offering. The global biopharmaceutical cold chain packaging market to grow at a CAGR of 4.14% over the period 2014-2019. The report, Global Biopharmaceutical Cold Chain Packaging Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA, and APAC; it also covers the landscape of the global biopharma cold chain packaging market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Outsourcing of pharmaceutical packaging is allowing pharmaceutical companies to reduce inventory and storage costs, and manufacturing time. As a result, more vendors are looking to opt for single-use disposable products to focus on the development of enhanced biopharmaceuticals. According to the report, the implementation of strict regulations on biopharma product packaging by government authorities to drive the market in the forecast period. Further, the report states that factors such as inefficient product labeling processes and complexities in procurement and supply chain processes make it difficult for labeling companies to collect accurate data from sources such as manufacturers and distributors. Key vendors - Amcor - CCL Industries - Clondalkin Group - Gerresheimer Other prominent vendors - Air Packaging Technologies - Allergan Pharmaceuticals - Aptargroup - Becton, Dickinson - Bemis Company - Capsugel - Cardinal Health - Catalent Pharma Solutions - Chesapeake - WS Packaging - EUROMEDEX - Global Closure Systems - Intrapac Group - Klockner Pentaplast Group - Manufacturing Applications eXperts - NNE - Nypro - Owens-Illinois - RPC Group - Schaefer Technologies - Schott - Schott AG - Steripack - Vitro - West Pharmaceutical Services - Wihuri Group - Winpak Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Market landscape Part 06: Market segmentation by type of material Part 07: Geographical segmentation Part 08: Market drivers Part 09: Impact of drivers Part 10: Market challenges Part 11: Impact of drivers and challenges Part 12: Market trends Part 13: Vendor landscape Part 14: Key vendor analysis Part 15: Appendix For more information visit http://www.researchandmarkets.com/research/63..._biopharma
AGN: 255.19 (-3.81), WST: 55.30 (+0.20), BMS: 44.99 (+2.88)
Allergan buys AqueSys in cash and future commercialisation milestone payments
M2 - Tue Oct 20, 4:39AM CDT
Pharmaceutical company Allergan (NYSE:AGN) disclosed on Monday the completion of the acquisition of AqueSys for a cash payment of USD300m up-front and potential regulatory approval and commercialisation milestone payments related to the latter's lead development product, XEN45.
AGN: 255.19 (-3.81)
CEDARS/ASPENS announces it has received Annual Sponsorships supporting its mission in the field of Ophthalmology.
Business Wire - Mon Oct 19, 3:25PM CDT
Ken Beckman, MD, President of CEDARS/ASPENS has stated, "We would like to extend our sincere thanks to Allergan, Bausch + Lomb, Shire, and Omeros for their annual support of CEDARS/ASPENS and for their enthusiasm and foresight in supporting the Society. These Annual Sponsorships as well as our Conference Sponsorships allow us to continue our work in shaping the future of anterior segment care through Innovation, Collaboration, and Education (I-- C-- E.) We look forward to working with each of our Annual Sponsors on various I-- C-- E initiatives."
AGN: 255.19 (-3.81)
Allergan to Present New Data for VIBERZI(TM) (eluxadoline) at the American College of Gastroenterology 2015 Annual Scientific Meeting
PR Newswire - Mon Oct 19, 7:15AM CDT
Allergan plc today announced that three data posters/presentations for eluxadoline will be presented during the American College of Gastroenterology 2015 Annual Scientific Meeting in Honolulu, HI, October 16-21, 2015. The presentations will feature data from eluxadoline's Phase III clinical trials in irritable bowel syndrome with diarrhea (IBS-D). VIBERZI(TM) (eluxadoline) was approved by the FDA on May 27, 2015 for the treatment of adults with IBS-D and is currently awaiting DEA scheduling.
AGN: 255.19 (-3.81)
Allergan Successfully Completes AqueSys Acquisition, Adding XEN45 Minimally Invasive Implantable Shunt for Glaucoma
PR Newswire - Mon Oct 19, 7:00AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.
AGN: 255.19 (-3.81)
Physician Dispensed Cosmeceuticals - Global Strategic Business Report 2015 - Physician Dispensed Skin Care Products, and Physician Dispensed Eyelash Products
M2 - Mon Oct 19, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t3kzrp/physician) has announced the addition of the "Physician Dispensed Cosmeceuticals - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Physician Dispensed Cosmeceuticals in US$ Thousand by the following Segments: Physician Dispensed Skin Care Products, and Physician Dispensed Eyelash Products. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 74 companies including many key and niche players such as - Allergan Plc. (US) - SkinMedica, Inc. (US) - Athena Cosmetics, Inc. (US) - Biopelle, Inc. (US) - Clinique Laboratories, LLC (US) - iS CLINICAL (US) - Jan Marini Skin Research, Inc. (US) - La Roche-Posay Laboratoire Pharmaceutique (France) - Neutrogena Corp. (US) - Obagi Medical Products, Inc. (US) - Pacific Bioscience Laboratories Inc. (US) - SkinCeuticals (US) - Solta Medical, Inc. (US) - Stiefel Laboratories, Inc. (US) Key Topics Covered: 1. Industry Overview 2. Growth Drivers And Market Trends 3. Competition 4. An Insight Into Market Barriers 5. Distribution Scenario 6. Aesthetics Market: A Brief Insight 7. Product Overview 8. Recent Industry Activity 9. Focus On Select Global Players 10. Global Market Perspective Total Companies Profiled: 74 (including Divisions/Subsidiaries - 79) - The United States (60) - Canada (5) - Europe (12) - - France (6) - - Germany (2) - - The United Kingdom (2) - - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (1) - Africa (1) For more information visit http://www.researchandmarkets.com/research/t3kzrp/physician
AGN: 255.19 (-3.81)
How Short Sellers Run this Market: Part 1
at The Street - 1 hr 5 mins ago
First, the sectors where shorts are making big money.
KMI: 30.04 (-1.38), AGN: 255.19 (-3.81), HCA: 65.91 (-5.29), VRX: 101.29 (-17.32), SWKS: 80.45 (+2.78), CYH: 27.21 (-13.34), NXPI: 95.40 (+4.08), AVGO: 124.48 (+3.98), HRZN: 9.94 (+0.20)
RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off
at The Street - 2 hrs 2 mins ago
The selloff in specialty pharmaceutical stocks has found a new "irrational low," following Wednesday's attack on Valeant Pharmaceuticals, according to RBC Capital Markets.
AGN: 255.19 (-3.81), ENDP: 49.51 (-4.95), INSY: 22.00 (-1.66), VRX: 101.29 (-17.32), SGNT: 15.57 (-0.49), IBB: 304.36 (-0.10), TEVA: 56.07 (-1.85)
Trigeminal Neuralgia Pipeline Review, H2 2015 - 4 Companies & 5 Drug Profiles
M2 - Thu Oct 22, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t353hr/trigeminal) has announced the addition of the "Trigeminal Neuralgia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Trigeminal Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Trigeminal Neuralgia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Convergence Pharmaceuticals Ltd. - Merz Pharma GmbH & Co. KgaA - Trigemina, Inc. Drug Profiles - (naltrexone hydrochloride clonidine hydrochloride) - incobotulinumtoxin A - onabotulinumtoxin A - oxytocin - raxatrigine hydrochloride For more information visit http://www.researchandmarkets.com/research/t353hr/trigeminal
AGN: 255.19 (-3.81)
Valeant Dives As Short Seller Alleges Pharmacy Fraud
at Investor's Business Daily - Wed Oct 21, 4:02PM CDT
Embattled drugmaker Valeant Pharmaceuticals (VRX) tumbled nearly 40% Wednesday to a two-year low and closed down 19.2%, as short-selling outfit Citron Research charged it with a complex fraud involving multiple specialty pharmacies. Valeant responded...
AGN: 255.19 (-3.81), ENDP: 49.51 (-4.95), VRX: 101.29 (-17.32)
Ocular (OCUL) Initiates Third Phase III Study on Dextenza
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 3:25PM CDT
Ocular (OCUL) initiated patient enrolment in the third phase III study on Dextenza for the treatment of post-surgical ocular inflammation and pain.
AGN: 255.19 (-3.81), OCUL: 15.10 (-0.22), NVS: 92.25 (+0.66)
Allergan Issues Statement On Specialty Pharmacy Utilization
PR Newswire - Wed Oct 21, 11:07AM CDT
Allergan plc (NYSE: AGN), today issued the following statement regarding specialty pharmacy utilization.
AGN: 255.19 (-3.81)
Next Support Level for Allergan (AGN) is $248.35
Comtex SmarTrend(R) - Wed Oct 21, 9:05AM CDT
Allergan (NYSE:AGN) has opened bearishly below the pivot of $265.04 today and has reached the first level of support at $255.88. Investors may be interested in a cross of the next downside pivot targets of $248.35 and $231.66.
AGN: 255.19 (-3.81)
Allergan Expands Dry Eye Portfolio With Launch Of REFRESH OPTIVE® Gel Drops
PR Newswire - Wed Oct 21, 7:01AM CDT
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the launch of the over-the-counter artificial tear REFRESH OPTIVE® Gel Drops, a new aqueous gel expertly designed for patients who need or desire a more viscous artificial tear option to relieve their Dry Eye symptoms. From REFRESH®, the creators of the number one doctor recommended brand of artificial tears1, new REFRESH OPTIVE® Gel Drops are formulated with Glycerin and a unique blend of the active ingredient CMC which binds to the eye surface to provide long-lasting relief from Dry Eye discomfort.
AGN: 255.19 (-3.81)
SmarTrend Watching for Potential Rebound in Shares of Allergan After 3.62% Loss
Comtex SmarTrend(R) - Tue Oct 20, 3:45PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $257.50 to a high of $274.19. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $261.17 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 255.19 (-3.81)
Cempra Antibiotic Meets Endpoints, Adverse Events Concerning
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:35PM CDT
Cempra, Inc. (CEMP) announced positive top-line results from a global, phase III study on pipeline candidate intravenous to oral solithromycin.
AGN: 255.19 (-3.81), PFE: 33.15 (-0.31), CEMP: 17.03 (-0.01)
Supernus Inks Trokendi XR Settlement Agreement with Endo
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:25PM CDT
Supernus (SUPN) inked a settlement agreement with Par Pharmaceutical (Endo's wholly owned subsidiary) for an ongoing patent litigation regarding Trokendi XR.
AGN: 255.19 (-3.81), ENDP: 49.51 (-4.95), ADHD: 6.48 (-0.01), SUPN: 15.31 (-0.50)
Rotation Is Enough to Make Your Head Spin
at The Street - Tue Oct 20, 1:17PM CDT
Bad news isn't always a bad thing.
AMZN: 566.29 (+10.52), TSLA: 214.62 (+4.53), VRX: 101.29 (-17.32), HOG: 47.40 (+0.37), LMT: 216.74 (+5.18), ETN: 54.75 (+2.23), CLX: 123.30 (+1.24), UTX: 99.71 (+1.74), DAL: 50.79 (+1.35), CELG: 116.25 (+0.33), AGN: 255.19 (-3.81), GILD: 102.01 (+0.28), IBM: 144.54 (+3.62), GOOGL: 681.92 (+10.12), DOV: 65.05 (+3.17), PG: 75.02 (+1.43), PPG: 103.76 (+3.12), REGN: 520.57 (+2.04)
Global Physician Dispensed Cosmeceutical Industry - Reportlinker Review
PR Newswire - Tue Oct 20, 11:58AM CDT
This report analyzes the worldwide markets for Physician Dispensed Cosmeceuticals in US$ Thousand by the following Segments: Physician Dispensed Skin Care Products, and Physician Dispensed Eyelash Products. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 74 companies including many key and niche players such as -
AGN: 255.19 (-3.81)
ModiFace Launches Live Facial Rejuvenation and Enhancement Mirror in Partnership With Allergan Canada
Marketwired - Tue Oct 20, 8:01AM CDT
ModiFace, the leading creator of augmented reality technology for the beauty and medical aesthetic industries, today announces the upcoming availability of its rejuvenation and enhancement mirror that simulates the effects of JUVEDERM(R) facial filler, in real time video. This new technology allows those interested in facial revitalization treatments to view the potential results by looking at the ModiFace-powered digital mirror. The results are photo-realistic, and are shown with full 3D rendering, meaning that addition of volume and lifting of the face can be observed from all angles exactly as one would look into a regular mirror. You can apply over 10 JUVEDERM(R) treatment effects such as smoothing smile lines, enhancing lips and lifting cheeks.
AGN: 255.19 (-3.81)
Global BioPharma Cold Chain Packaging Market 2015-2019
M2 - Tue Oct 20, 6:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/639gfl/global_biopharma) has announced the addition of the "Global BioPharma Cold Chain Packaging Market 2015-2019" report to their offering. The global biopharmaceutical cold chain packaging market to grow at a CAGR of 4.14% over the period 2014-2019. The report, Global Biopharmaceutical Cold Chain Packaging Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA, and APAC; it also covers the landscape of the global biopharma cold chain packaging market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Outsourcing of pharmaceutical packaging is allowing pharmaceutical companies to reduce inventory and storage costs, and manufacturing time. As a result, more vendors are looking to opt for single-use disposable products to focus on the development of enhanced biopharmaceuticals. According to the report, the implementation of strict regulations on biopharma product packaging by government authorities to drive the market in the forecast period. Further, the report states that factors such as inefficient product labeling processes and complexities in procurement and supply chain processes make it difficult for labeling companies to collect accurate data from sources such as manufacturers and distributors. Key vendors - Amcor - CCL Industries - Clondalkin Group - Gerresheimer Other prominent vendors - Air Packaging Technologies - Allergan Pharmaceuticals - Aptargroup - Becton, Dickinson - Bemis Company - Capsugel - Cardinal Health - Catalent Pharma Solutions - Chesapeake - WS Packaging - EUROMEDEX - Global Closure Systems - Intrapac Group - Klockner Pentaplast Group - Manufacturing Applications eXperts - NNE - Nypro - Owens-Illinois - RPC Group - Schaefer Technologies - Schott - Schott AG - Steripack - Vitro - West Pharmaceutical Services - Wihuri Group - Winpak Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Market landscape Part 06: Market segmentation by type of material Part 07: Geographical segmentation Part 08: Market drivers Part 09: Impact of drivers Part 10: Market challenges Part 11: Impact of drivers and challenges Part 12: Market trends Part 13: Vendor landscape Part 14: Key vendor analysis Part 15: Appendix For more information visit http://www.researchandmarkets.com/research/63..._biopharma
AGN: 255.19 (-3.81), WST: 55.30 (+0.20), BMS: 44.99 (+2.88)
Allergan buys AqueSys in cash and future commercialisation milestone payments
M2 - Tue Oct 20, 4:39AM CDT
Pharmaceutical company Allergan (NYSE:AGN) disclosed on Monday the completion of the acquisition of AqueSys for a cash payment of USD300m up-front and potential regulatory approval and commercialisation milestone payments related to the latter's lead development product, XEN45.
AGN: 255.19 (-3.81)
CEDARS/ASPENS announces it has received Annual Sponsorships supporting its mission in the field of Ophthalmology.
Business Wire - Mon Oct 19, 3:25PM CDT
Ken Beckman, MD, President of CEDARS/ASPENS has stated, "We would like to extend our sincere thanks to Allergan, Bausch + Lomb, Shire, and Omeros for their annual support of CEDARS/ASPENS and for their enthusiasm and foresight in supporting the Society. These Annual Sponsorships as well as our Conference Sponsorships allow us to continue our work in shaping the future of anterior segment care through Innovation, Collaboration, and Education (I-- C-- E.) We look forward to working with each of our Annual Sponsors on various I-- C-- E initiatives."
AGN: 255.19 (-3.81)
Allergan to Present New Data for VIBERZI(TM) (eluxadoline) at the American College of Gastroenterology 2015 Annual Scientific Meeting
PR Newswire - Mon Oct 19, 7:15AM CDT
Allergan plc today announced that three data posters/presentations for eluxadoline will be presented during the American College of Gastroenterology 2015 Annual Scientific Meeting in Honolulu, HI, October 16-21, 2015. The presentations will feature data from eluxadoline's Phase III clinical trials in irritable bowel syndrome with diarrhea (IBS-D). VIBERZI(TM) (eluxadoline) was approved by the FDA on May 27, 2015 for the treatment of adults with IBS-D and is currently awaiting DEA scheduling.
AGN: 255.19 (-3.81)
Allergan Successfully Completes AqueSys Acquisition, Adding XEN45 Minimally Invasive Implantable Shunt for Glaucoma
PR Newswire - Mon Oct 19, 7:00AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.
AGN: 255.19 (-3.81)
Physician Dispensed Cosmeceuticals - Global Strategic Business Report 2015 - Physician Dispensed Skin Care Products, and Physician Dispensed Eyelash Products
M2 - Mon Oct 19, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t3kzrp/physician) has announced the addition of the "Physician Dispensed Cosmeceuticals - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Physician Dispensed Cosmeceuticals in US$ Thousand by the following Segments: Physician Dispensed Skin Care Products, and Physician Dispensed Eyelash Products. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 74 companies including many key and niche players such as - Allergan Plc. (US) - SkinMedica, Inc. (US) - Athena Cosmetics, Inc. (US) - Biopelle, Inc. (US) - Clinique Laboratories, LLC (US) - iS CLINICAL (US) - Jan Marini Skin Research, Inc. (US) - La Roche-Posay Laboratoire Pharmaceutique (France) - Neutrogena Corp. (US) - Obagi Medical Products, Inc. (US) - Pacific Bioscience Laboratories Inc. (US) - SkinCeuticals (US) - Solta Medical, Inc. (US) - Stiefel Laboratories, Inc. (US) Key Topics Covered: 1. Industry Overview 2. Growth Drivers And Market Trends 3. Competition 4. An Insight Into Market Barriers 5. Distribution Scenario 6. Aesthetics Market: A Brief Insight 7. Product Overview 8. Recent Industry Activity 9. Focus On Select Global Players 10. Global Market Perspective Total Companies Profiled: 74 (including Divisions/Subsidiaries - 79) - The United States (60) - Canada (5) - Europe (12) - - France (6) - - Germany (2) - - The United Kingdom (2) - - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (1) - Africa (1) For more information visit http://www.researchandmarkets.com/research/t3kzrp/physician
AGN: 255.19 (-3.81)
